Edgemoor Investment Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $530K | Buy |
2,435
+2
| +0.1% | +$444 | 0.04% | 119 |
|
|
2025
Q4 | $556K | Sell |
2,433
-2,174
| -47% | -$495K | 0.04% | 120 |
|
|
2025
Q3 | $1.07M | Buy |
4,607
+2,177
| +90% | +$443K | 0.08% | 97 |
|
|
2025
Q2 | $451K | Buy |
2,430
+111
| +5% | +$20.6K | 0.04% | 125 |
|
|
2025
Q1 | $486K | Buy |
2,319
+1
| +0% | +$194 | 0.04% | 118 |
|
|
2024
Q4 | $412K | Buy |
2,318
+201
| +9% | +$37K | 0.04% | 124 |
|
|
2024
Q3 | $418K | Sell |
2,117
-34
| -2% | -$6.35K | 0.04% | 120 |
|
|
2024
Q2 | $369K | Buy |
2,151
+2
| +0.1% | +$331 | 0.03% | 121 |
|
|
2024
Q1 | $391K | Buy |
2,149
+182
| +9% | +$31.4K | 0.04% | 118 |
|
|
2023
Q4 | $305K | Sell |
1,967
-272
| -12% | -$39.7K | 0.03% | 133 |
|
|
2023
Q3 | $334K | Buy |
2,239
+2
| +0.1% | +$294 | 0.04% | 121 |
|
|
2023
Q2 | $301K | Buy |
2,237
+2
| +0.1% | +$293 | 0.03% | 128 |
|
|
2023
Q1 | $356K | Sell |
2,235
-100
| -4% | -$15.3K | 0.04% | 121 |
|
|
2022
Q4 | $377K | Sell |
2,335
-189
| -7% | -$29K | 0.05% | 124 |
|
|
2022
Q3 | $339K | Sell |
2,524
-370
| -13% | -$53.1K | 0.05% | 114 |
|
|
2022
Q2 | $443K | Buy |
2,894
+227
| +9% | +$34.7K | 0.06% | 112 |
|
|
2022
Q1 | $432K | Buy |
2,667
+191
| +8% | +$27.7K | 0.05% | 116 |
|
|
2021
Q4 | $335K | Buy |
+2,476
| New | +$292K | 0.03% | 118 |
|
|
2021
Q3 | – | Sell |
-2,386
| Closed | -$269K | – | 137 |
|
|
2021
Q2 | $269K | Sell |
2,386
-35
| -1% | -$3.94K | 0.03% | 118 |
|
|
2021
Q1 | $262K | Buy |
2,421
+101
| +4% | +$10.8K | 0.03% | 115 |
|
|
2020
Q4 | $249K | Buy |
2,320
+22
| +1% | +$2.11K | 0.03% | 112 |
|
|
2020
Q3 | $201K | Buy |
+2,298
| New | +$216K | 0.02% | 123 |
|
|
2019
Q3 | – | Sell |
-2,775
| Closed | -$202K | – | 132 |
|
|
2019
Q2 | $202K | Hold |
2,775
| – | – | 0.03% | 134 |
|
|
2019
Q1 | $224K | Hold |
2,775
| – | – | 0.03% | 128 |
|
|
2018
Q4 | $256K | Hold |
2,775
| – | – | 0.04% | 115 |
|
|
2018
Q3 | $262K | Hold |
2,775
| – | – | 0.03% | 118 |
|
|
2018
Q2 | $257K | Sell |
2,775
-257
| -8% | -$25.1K | 0.03% | 119 |
|
|
2018
Q1 | $287K | Hold |
3,032
| – | – | 0.04% | 117 |
|
|
2017
Q4 | $311K | Buy |
3,032
+300
| +11% | +$28.3K | 0.04% | 117 |
|
|
2017
Q3 | $243K | Sell |
2,732
-160
| -6% | -$12.2K | 0.03% | 126 |
|
|
2017
Q2 | $210K | Buy |
+2,892
| New | +$194K | 0.03% | 130 |
|
Other funds holding ABBV
VCM
VPM
Edgemoor Investment Advisors's ABBV Position: Q1 2026 in Review
Edgemoor Investment Advisors increased its AbbVie (ABBV) stake by 0.08% in Q1 2026, buying an estimated $444 and bringing the position to 2,435 shares worth $530K. The position accounts for 0.04% of the portfolio, ranked #119.
Edgemoor Investment Advisors first reported a position in ABBV in Q2 2017 and has held it in 31 quarters since. The position peaked at $1.07M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Edgemoor Investment Advisors held 2,435 shares of AbbVie worth $530K as of Q1 2026.
- Edgemoor Investment Advisors bought 2 AbbVie shares in Q1 2026, an estimated $444.
- AbbVie made up 0.04% of Edgemoor Investment Advisors's portfolio in Q1 2026, its #119 holding.
- Edgemoor Investment Advisors first reported a position in AbbVie in Q2 2017 and has held it in 31 quarters since.
- Edgemoor Investment Advisors's AbbVie position peaked at $1.07M in Q3 2025.
- 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Edgemoor Investment Advisors's 13F filing for Q1 2026, filed 13 May 2026.